General Biologicals Corporation

NT$8.70As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4117Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (7.63%)
Div yield —
ROE 108.50%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.79
PE TTM 1.139
TSR TTM (43.14%)
Mkt cap NT$615.9M
ROIC (4.72%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$11
27.25%
(50.48%)
Hold 10|11|2|6|12
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.12
0.12
0.12
0.12
(9.27%)
(6.22%)
(0.96%)
1.12%
RevenueNT$M
51.23
49.70
49.00
48.70
1.94%
(4.80%)
(7.75%)
(7.41%)
Peers (US$18.13M)
Cap (US$)
PE
23.68M
160.9x
Capital
TTM
5Y
10Y
Leveragex
1.802
(0.044)
(0.032)
EBIT/Intx
1.033
0.713
0.792
Own earn%
20.45
3.67
7.45
Sh yield%
10.26
21.30
22.90
Owners
Insiders/Inst%
10.33
88.39
Short interest%
2.95
SBC / revenue%
3.31
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
3
Op margin range%
15–19
$1 testx
—
Incr. ROIC%
12